OBJECTIVE: A single "supraphysiological" course of exogenous corticosteroids is recommended between 24e34 weeks' gestation to minimize the adverse sequelae associated with prematurity. The 24-hour profile of endogenous corticosteroids normally follows a diurnal rhythm with the highest serum level occurs between 5am-11am and nadir over 12 hours. We hypothesized that exogenous corticosteroids given during the nadir state of endogenous corticosteroids activity could alter maternal and fetal glucose homeostasis. STUDY DESIGN: A retrospective study from January 2010 to December 2017. Eligible for analysis were: singleton pregnancies between 24 e 34 weeks' gestation who were given a single course of intramuscular betamethasone. Single course comprised of two separate doses of 12 mg given 24 hours apart. Each woman was allocated into one of the four pre-defined groups based on the time the intramuscular betamethasone was administered; Group 1 (5am-11am), group 2 (11am-5pm), group 3 (5pm-11pm) and group 4 (11pm-5am). The primary outcome of the study was the incidence of neonatal hypoglycemia, glucose ˂ 40 mg/dL at any time. RDS, TTN and need for ventilation were considered secondary outcomes. Chi-square test was used for statistical analysis. RESULTS: A total of 697 eligible cases were assessed, of which 183 (26.3%) delivered ˂ 34 weeks, 185 (26.5%) delivered between 34 e 37 weeks, and 329 (47.2%) delivered after 37 weeks' gestation. Subanalysis of the 190 women (27.3%) who delivered between 48 hours e 14 days following first betamethasone injection demonstrated that the incidence of neonatal hypoglycemia was significantly higher in group 3 (35.4%) when betamethasone was administered between 5pm to 11pm, that coincide with the nadir state of maternal endogenous corticosteroids activity, compared to group 1 (21.1%), group 2 (13.7%) and group 4 (12.9%) ( Table 1) . No differences were demonstrated in any of the secondary outcomes. CONCLUSION: The time of betamethasone administration might be critical in the overall risk of the neonate to develop hypoglycemia. The highest risk of neonatal hypoglycemia is when a course of maternal antenatal betamethasone is administered between 5pm-11pm. A plausible mechanism may be that exogenous corticosteroids, administered during the maternal nadir state of endogenous corticosteroids activity, lead to an "acute transient maternal hyperglycemia" and neonatal hypoglycemia secondary to insulin overshoot. OBJECTIVE: Antenatal magnesium sulfate treatment is widely used for fetal neuroprotection in women at risk of preterm delivery. But, some studies have recently questioned that in utero magnesium sulfate exposure is associated with an increased risk of necrotizing enterocolitis (NEC). In this study, we examined the association between antenatal magnesium sulfate exposure and risk of necrotizing enterocolitis (NEC) in preterm deliveries (<32 weeks of gestation). STUDY DESIGN: This retrospective cohort study (from January 2012 to December 2016) included neonates delivered from 24+0 weeks to 31+6 weeks of gestation. The subjects were classified into three groups; period 1 (from January 2012 to December 2013 when antenatal magnesium sulfate treatment for neuroprotection was not adopted), period 2 (from January 2014 to March 2016 when the treatment was routinely used), and period 3 (from April 2016 to December 2016 when the treatment was abandoned due to its potential risk of NEC). The primary outcome was NEC and neonatal death from NEC. We also performed a secondary analysis to compare the outcomes between the exposure and non-exposure group regardless of the time period. RESULTS: A total of 598 neonates were included in this study, 270 in the period 1, 264 in the period 2, and 64 in the period 3. More than half of the neonates (60.6%) were exposed to magnesium sulfate in the period 2 compared with 16.2% and 14.0% in the period 1 and 3, respectively. There was no significant differences in the rate of NEC (23.0% in the period 1, 18.2% in the period 2, and 23.4% in the period 3, P¼0.346), and neonatal death due to NEC (0.7% the period 1, 2.3% in the period 2, 1.6% in the period 3, P¼0.347) among the three periods. The rates of severe NEC (grade II), overall neonatal death and other neonatal outcomes were not significantly different among the three periods. In the secondary analysis, 213 (35.6%) were exposed to antenatal magnesium sulfate and 126 (59.2%) of them were used for neuroprotection. The rates of NEC (exposure group vs. non-exposure group: 17.8% vs. 22.6%, P ¼0.171), and neonatal death due to NEC (exposure group vs. nonexposure group: 1.4% vs. 1.6%, P¼0.885) were not significantly different between the two groups. The rates of severe NEC (grade II), overall neonatal death and other neonatal outcomes of the two groups were similar. CONCLUSION: Antenatal magnesium sulfate treatment for fetal neuroprotection was not associated with NEC, neonatal death due to NEC and other short-term neonatal outcome.
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